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Summary
 Background Remarkable advance in the knowledge of the biology and treatment of chronic lymphocytic leu-
kaemia (CLL) has been noted in recent years. CLL resembles several heterogeneous diseases with 
variable morphological features. New agents with antileukemic activity have been introduced re-
cently for CLL patients, which improved the treatment results. Fludarabin has shown its effi cacy in 
CLL both as a treatment of choice and in combination with conventional cytostatic agents. Clinical 
and haematological features of B-CLL in persons affected by the Chernobyl accident in the last pe-
riod are presented.
 Aim The aim of this study was the comparison of two chemotherapy different schemes for B-CLL treat-
ment.
 Materials/Methods The study was based on 32 patients with diagnosis of B-CLL who were treated at the Hematology 
Department. Depending upon the protocol all patients were classifi ed in two subgroups: I – fl udara-
bine monotherapy treatment, II – fl udarabine with combination with other chemotherapy prepa-
rations.
 Results of the treatment are analyzed for 16 patients after different chemotherapy regimens. A combined 
fl udarabine and cyclophosphamide regimen has been shown to improve long-term complete and 
partial remission in the majority of patients as compared with a more conservative approach.
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BACKGROUND
Clinical and haematological features of B-cell chronic lym-
phoid leukaemia and results of management with various 
chemotherapy protocols are presental for persons exposed 
to ionizing radiation after the Chernobyl nuclear power 
plant accident (CNA). A combination of fl udarabine with 
cyclophosphamide was found to induce a long-term com-
plete or partial remission in a large part of patients in con-
trast to the use of traditional protocols. Cytopenia is regard-
ed as one of the side-effects of the fl udarabine treatment 
along with infections and bleeding related to decreased 
platelet counts.
A clinical course of B-cell chronic lymphoid leukaemia (B-
CLL) in people exposed to ionizing radiation when work-
ing in emergency situations at the CNA and living on ra-
dio-contaminated territories long time after the accident 
is characterized by a rapid progress and resistance to tradi-
tional chemotherapy protocols [1].
Application of purine analogue (i.e. pentostatine, cladrib-
ine, fl udarabine) a prospective drugs in the management 
of B-CLL [2–6] for the last two decades has led to a signifi -
cant improvement in the treatment outcome [7,8].
The B-CLL origin is now thought to be related to a decrease 
of in cell sensitivity to apoptosis. The fl udarabine effect in-
volves a direct apoptotic impact on B-cells through the de-
pression of DNA synthesis and especially DNA repair [9].
Clinical trials with fl udarabine have proven its action on the 
lymphoid cell line and its effi cacy in chronic lymphopro-
liferative disorders, including the B-CLL cases progressing 
under alkylating agents and standard chemotherapy pro-
tocols [10–13].
Fludarabine monotherapy was not always effective enough; 
therefore, some other cytostatic agents have been added to 
improve the response. A combination of fl udarabine with 
cyclophosphamide provides a response in 71–89% [7].
AIM
We present here the results of our study of the effi cacy of 
different treatment schemes in the population affected by 
the Chernobyl accident.
METHODS
The study was carried out on 12 participants of emergen-
cy work at the CNA and four residents of radio-contam-
inated territories all with B-CLL, aged 42–76, and treat-
ed at the Hematology Department of SCRM of MSA of 
Ukraine (1st group). Doses of external exposure were es-
timated during dosimetry control after decontamination 
work in four patients and varied from 0.04 to 0.25 Gy. Out 
of 8 clean-up workers 5 were exposed in the period from 
April to October 1986, and other three – in 1987. According 
to dosimetry estimates [14] the mean doses to those work-
ers in 1986 were 0.13 Gy and to those in 1987 – were 0.05 
Gy. Total doses of chronic exposure residents of the con-
taminated territories varied from 0.05 to 0.04 Gy. The con-
trol group included 16 B-CLL patients who were exposed 
to natural ionizing radiation (2nd group). Age and gender 
were comparable in both groups. The latent phase in the 1st 
group was 1–10 (6.9±2.02) months. The pre-clinical phase 
in the control group ranged between 12 and 96 (23.1±7.4) 
months. Clinical and hematological characteristics of the 
patients is showns in Table 1.
Peripheral lymph nodes enlargement (1 to 5 cm) in two re-
gional groups and was found in both groups with splenom-
egaly (150/80–180/80 mm) and ventral lymph nodes en-
largement (10 to 49 mm) by ultrasonography.
Elevated white blood cell counts, of 13–531×109/L (mean 
100.8±79.71) 54–95% lymphocytosis (mean 77.9±9.58) 
were observed. Lymphocytes with mature cell morphologi-
cal signs (high cytoplasm/nucleus ratio, condensed nucle-
ar chromatin, basophilic cytoplasm) were prevalent in lym-
phocytograms. There were 10–30% of prolymphocytes (in 
2/1 patients respectively), which corresponded to B-CLL 
morphologically atypical form. The hemoglobin level was 
28–154 g/L (mean 102.9±18.16),and the platelets count 
was 30 to 300×109/L (mean 156.25±50.53).
Myelograms showed an increase in myelokaryocytes count 
of up to 360,000 (mean 213,200) at the expense of a high 
number of lymphocytes (80±11 mean) and narrowing of 
myeloid and erythroid hemopoietic roots. Megakaryocytes 
were represented by single cells.
Trepanobiopsy studies from the iliac bone indicated hyper-
plastic bone marrow with lymphoid elements of a mature 
lymphocyte type fi lling out all the intertrabecular spaces. 
A diffuse type of bone marrow damage was prevalent. A fo-
cal-diffuse type of the BM injury was observed at the initial 
stage A. Myeloid (granulocytic) and erythroid hemopoiet-
ic tissues were represented by single small islets. The meg-
akaryocyte root was narrowed with a small amount of most-
ly mature forms. Pronounced reduction of adipose tissue 
was registered with a myeloid/adipose tissue ratio of 5–7:1. 
Moderate bone tissue resorption with fi brotic foci forma-
tion, deformation of sinuses and their quantitative decrease 
were present.
Patients
1st group (n=16) 2nd group (n=16)
 Males 16 16
 Age 53±7 54.5±6.71
 Phase В 13 10
 Phase С 3 6
 Hb
 ≤100 g/L 6 8
 ≥100 g/L 10 8
 Platelets
 ≤100×109/L 3 2
 ≥100×109/L 13 14
 WBC
 ≤100×109/L 11 13
 ≥100×109/L 5 3
Table 1. Clinical-hematological characteristics of patients.
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What was typical was loss of structure odue to diffuse infi ltra-
tion with a lymphoid tissue, mainly of small lymphocytes.
Immunophenotype studies of B-cell markers have shown 
that 50 to 92% of the circulating blood or BM cells in the 
exposed persons, and 54 to 90% cells in the 2 group rep-
resented a CD45+10–19+20+5+22(dim)+23+DR+ phenotype. The 
T-cell showed an altered ratio of CD4+ and CD8+ cells with 
the prevalence of the latter. The phase of leukaemia was de-
fi ned for all patients using available data according to clini-
cal phase classifi cation by Binet [15,16].
Depending upon the applied protocols, patients from 
both groups were classifi ed in two subgroups. The fi rst 
subgroup of exposed patients included 14 (males aged 
41–72, mean 53 years) who received fl udarabine as mon-
otherapy or in combination with other chemotherapy 
agents. In three cases, resistance was found to previous 
standard chemotherapy with leukeran and prednisolone 
both with that to CHOP, CHOP-Bleo, COP and VAMP pro-
grames. Other 11 patients received fl udarabine as an ini-
tial agent. The second group included two patients, aged 
51 and 74 who received standard polychemotherapy pro-
tocols. In the control the fi rst subgroup of 12 persons re-
ceived fl udarabine, and the other group included four pa-
tients treated traditionally.
Fludarabine monotherapy was administered in a 50 mg/day 
dose i.v. with a low infusion rate for 5 days; the same protocol 
was used in combination with cyclophosphamide (fl udara-
bine 50 mg/day and cyclophosphamide 600 mg/day i.v. 
at a low rate) for 3 days. Treatment courses were repeat-
ed every 4 weeks.
Table 2 shows the number of patients treated by chemo-
therapy including fl udarabine.
Chemotherapy outcomes were assayed by the National 
Cancer Institute (NCI) Standard Scale (USA) [17].
RESULTS
Complete clinical-hematological remission lasting 16, 15 and 
9 months was obtained in three (21.4%) of patients exposed 
Who receivied fl udarabine. In one case, complete remission 
was established after 5 courses with previous resistance to 
standard chemotherapy. In two other cases, the complete 
remission was registered after 4 and 6 courses.
Partial remission lasting over 6 months was observed in 8 
patients (51.4%) after 2, 3, 4 and 5 courses; two of them 
were resistant to prior therapy (5–6 courses of leukeran 
with prednisolone, lymphocyte plasmopheresis, or either 
CHOP or COP).
DISCUSSION
The general response rate in fl udarabine therapy in this group 
was 72,8% which is corresponding the available data from 
medical literature. Progression was observed in two patients 
with infectious complications, in whom the use of fl udarabine 
induced the pronounced anaemia, therefore application of 
the drug was discontinued. Toxic effects such as alopecia or 
kidneys involvement were not observed, nausea and vomiting 
were stopped by antiemetics. In three cases prolonged leuko-
penia (28–37 days, WBC count 1.2×109/L) occurred after 3 
or 4 courses of fl udarabine. After the period of rest between 
courses the therapy was continued for up to 45 days; a new 
course of fl udarabine was initiated when the WBC count was 
over 2.0×109/L. In the second subgroup which receivied leuk-
eran or cyclophosphamide as monotherapy or in combina-
tion with prednisolone or courses of CHOP or COP polyche-
motherapy no complete clinical-hematological remission was 
observed, whereas partial remission in three patients lasted 
less than 3 months. The progression of the disease was been 
in 62.5% of patients from the second subgroup.
Table 3 shows the result of treatment.
CONCLUSIONS
The period of the WBC count doubled was faund to be much 
shorter in the Chernobyl NPP accident survivors than that in 
the controls. The course of B-CLL in the exposed patients is 
characterized by resistance and low sensitivity to traditional 
treatment. Fludarabine can be successfully used during peri-
od of acute clinical-hematological manifestations of B-CLL in 
patients resistant to standard polychemotherapy protocols as 
it provides long-term remission with an increase of the survival 
time. The present study is to be followed up in the future.
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